 
					
					
									
				
							
						
				FDA Issues Draft Guidance on AI in Medical Devices and Drug Development
On January 6, 2025, the U.S. Food & Drug Administration released two draft guidance documents…
 
					
					
									
				
							On January 6, 2025, the U.S. Food & Drug Administration released two draft guidance documents…
 
					
					
									
				
							New law limits methods health insurers and PBMs can use to delay and discourage access…
 
					
					
									
				
							On October 7, 2024, the U.S. Department of Health and Human Services (HHS) issued a…
 
					
					
									
				
							On December 4, 2024, Aimed Alliance hosted a webinar on HR.com titled “Supporting Women in…
 
					
					
									
				
							On November 14, 2024, Aimed Alliance and the Alliance for Patient Access (AfPA) hosted a…
 
					
					
									
				
							The U.S. Drug Enforcement Administration (DEA) has extended the temporary telemedicine flexibilities allowing providers to…
 
					
					
									
				
							The Coalition for Health AI (CHAI), a group of stakeholders that collaborate to drive the…
 
					
					
									
				
							On November 8, 2024, Aimed Alliance submitted feedback to the Maryland Prescription Drug Affordability Board…
 
					
					
									
				
							Currently, Medicare coverage for anti-obesity medications is limited to indications for diabetes and cardiovascular disease.…
 
					
					
									
				
							On October 10, 2024, the National AI Advisory Committee released its draft transition plan…
